Background
==========

Breast cancer is one of the most common causes of death from cancer among women. Significant but yet insufficient progress has been achieved due to the introduction of targeted therapeutics \[[@B1]\]. Nevertheless, advancing personalized medicine requires a detailed and comprehensive molecular characterization, particularly at the protein level. This project aims to advance the understanding of crosstalk between cancer-relevant signaling and metabolism.

Materials and methods
=====================

Based on a constructed flux distribution model, targets where chosen to be analyzed in breast cancer cell lines and tumor samples. The RPPA (reverse phase protein microarray) technology a micro-scaled dot-blot approach is used. RPPA allows to quantify protein expression and activation states in a large panel of samples. In addition, RPPA has a remarkable high sensitivity and is able to analyze many proteins in a single experiment. Therefore this method presents a powerful approach for targeted hypothesis-based proteome research \[[@B2]\].

Results
=======

As a first step, based on publically available transcript data a model describing the deregulation especially of glutamine and nitrogen metabolism in breast cancer was developed \[[@B3]\]. Key features of our model are currently evaluated by RPPA in cell lines representing the different breast cancer subtypes. Metabolic enzymes confirmed on the cell line level as de-regulated will be evaluated in tumor samples and tested as putative drug targets in *in vitro* models.

Conclusion
==========

Based on the bioinformatic model and proteomic validation our aim is to introduce options for new co-treatment concepts that target key metabolic enzymes to harm tumor cells and disable their malignant anabolic processes, as well as energy consumption. The resulting data will provide a basis to calculate new models explaining the metabolic shift in breast cancer cells and to identify signaling molecules that contribute to malignant transformation.
